Developer docs
API playgroundTry for free, no card

Search company profiles

CoreRx

Full company profile

uuid0002wny

Namestring
CoreRx
Legal namestring
CoreRx, Inc.
Company typeenum
Private
Founded yearint
2006
Descriptiontext

CoreRx, Inc. (now operating under the Bend Bioscience brand following a September 2025 unification) is a privately held pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Clearwater, Florida. Founded in 2006, the company provides end-to-end small molecule drug product development services spanning formulation design, analytical and stability testing, cGMP clinical manufacturing, and commercial manufacturing. CoreRx serves pharmaceutical and biotechnology companies requiring specialized capabilities in spray drying, particle engineering, oral bioavailability enhancement, multiparticulates, modified release formulations, oral solids and liquids, topical formulations, and powders for inhalation. The company emphasizes a domestic U.S. manufacturing footprint across three locations in Oregon, Georgia, and Florida, positioning itself as a supply-chain-resilient alternative to offshore CDMOs. Notable specialized offerings include complex oral dosage forms, advanced spray drying capabilities (with newly expanded commercial-scale suites in Bend, Oregon), and an integrated 'High Science / High Service' model that bundles preformulation through commercial manufacturing under one organizational roof.

The business operates on a project-based professional services model, generating revenue through negotiated contracts tied to formulation development, clinical manufacturing, and commercial supply scopes. Go-to-market is B2B enterprise field sales, with direct engagement of pharmaceutical sponsors and senior presence at industry conferences such as CPHI Milan. Pricing is not publicly disclosed and is described as quote-based on project scope. In April 2024, CoreRx acquired Societal CDMO, Inc. for approximately $130 million via tender offer, delisting Societal from Nasdaq and absorbing it as a wholly owned subsidiary; the combined entity was subsequently rebranded under the unified Bend Bioscience identity in September 2025. The company currently employs 101-250 people and has raised approximately $15 million across three funding rounds between 2015 and 2019. Leadership includes Todd R. Daviau as President and CEO, Bill Reid as Executive Director and Chief Operations Officer, and Bob Berg as Chief Financial Officer.

Short descriptiontext

CoreRx (now Bend Bioscience) is a privately held U.S. pharmaceutical CDMO providing end-to-end small molecule drug product development and manufacturing services — formulation design, analytical, clinical, and commercial cGMP manufacturing — to pharmaceutical and biotechnology companies across three U.S. locations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersClearwater, United States
HQ citystring
Clearwater
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO, contract manufacturing, drug formulation development, small molecule manufacturing, cGMP clinical manufacturing
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Miscellaneous Chemical Products2890
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

CDMO services providing formulation development, analytical services, clinical manufacturing, and commercial manufacturing for pharmaceutical companies. Revenue generated through project-based contracts for drug development and manufacturing services.

bendbioscience.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

CoreRx is a pharmaceutical contract development and manufacturing organization (CDMO) providing integrated formulation development, analytical, clinical manufacturing, and commercial manufacturing services for small molecule therapeutics. Its offerings span Design, Develop, and Manufacture service tiers with specialized capabilities in spray drying, particle engineering, oral bioavailability enhancement, multiparticulates, modified release, oral solids, oral liquids, powders for inhalation, and topicals. Operations are supported through three U.S. manufacturing locations in Oregon, Georgia, and Florida, with newly expanded cGMP suites in Bend, Oregon.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CoreRx operates as a pharmaceutical finished product Contract Development and Manufacturing Organization (CDMO), unified with Societal CDMO and Bend Bioscience under the Bend Bioscience brand. The company offers an integrated platform spanning Design, Develop, and Manufacture services for small molecule therapeutics. The portfolio includes specialized formulation capabilities such as Oral Bioavailability Enhancement (spray drying, particle engineering), Multiparticulates, Modified Release, Oral Dosage Form Design, Oral Solids, Oral Liquids, Powders for Inhalation, and Topicals. Service offerings encompass the full product lifecycle from Preformulation & Process Design through Analytical & Stability testing, cGMP Clinical Manufacturing, Commercial Manufacturing, Technology Transfer, Packaging, and Quality & Compliance. The company maintains world-class expertise across three U.S. locations in Oregon, Georgia, and Florida, with expanded cGMP capabilities in Bend, Oregon supporting spray drying, particle engineering, and complex oral dosage forms.

Product and service1 record
1Design Services
CategoryCore Service
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierNotableTypeStrategic or Co-development PartnerAnnounced on2025-04-04
Description

Development agreement for oral controlled release dosage form of STAR-LLD (lenalidomide), representing a co-development partnership for specialized pharmaceutical formulation.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Recipharm
TypeDirect peer
Description

European-headquartered CDMO focused on oral solids, inhalation, and topical dosage forms, with both clinical and commercial manufacturing. Closely comparable in scope to CoreRx's specialty small molecule drug product platform.

TypeDirect peer
Description

Pharmaceutical CDMO providing solid, semi-solid, and liquid dosage form development and manufacturing, including topicals and softgel capabilities—comparable dosage form breadth to CoreRx.

TypeDirect peer
Description

Specialty CDMO focused on particle engineering, spray drying, and bioavailability enhancement for oral dosage forms—directly comparable to CoreRx's spray drying and particle engineering 'High Science' platform.

TypeDirect peer
Description

Global CDMO offering formulation development, clinical and commercial manufacturing across oral, sterile, and inhalation dosage forms—directly comparable to CoreRx's small molecule drug product CDMO platform, though at much larger scale.

TypeDirect peer
Description

One of the world's largest CDMOs providing small molecule and biologic drug substance and drug product services. Comparable as a full-service pharmaceutical CDMO, with overlapping oral solid dose and complex formulation capabilities.

TypeBroad incumbent
Description

Operates a major pharmaceutical services division including oral solid dose, sterile, and API CDMO services. Overlaps directly with CoreRx's small molecule drug product offering as part of a much broader life sciences services portfolio.

TypeDirect peer
Description

Privately held pharmaceutical CDMO offering formulation development, analytical services, and clinical/commercial manufacturing for solid oral dosage forms, with similar integrated service scope to CoreRx.

TypeDirect peer
Description

CDMO providing small molecule API and finished dose development and manufacturing services, including controlled substances and high-potency compounds—comparable small molecule drug product focus.

TypeDirect peer
Description

Now a wholly owned subsidiary of CoreRx following the $130M 2024 acquisition; provides contract development and manufacturing for complex oral, topical, and nasal dosage forms, directly overlapping with CoreRx's formulation services.

TypeDirect peer
Description

Bend Bioscience was combined with CoreRx and Societal CDMO under a unified brand in September 2025, and historically offered formulation and GMP spray drying services—directly comparable specialized CDMO capability, now the parent brand.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CoreRx

Pharmaceutical Contract Development and Manufacturing (CDMO)corerxpharma.com

CoreRx (now Bend Bioscience) is a privately held U.S. pharmaceutical CDMO providing end-to-end small molecule drug product development and manufacturing services — formulation design, analytical, clinical, and commercial cGMP manufacturing — to pharmaceutical and biotechnology companies across three U.S. locations.

What CoreRx does

CoreRx, Inc. (now operating under the Bend Bioscience brand following a September 2025 unification) is a privately held pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Clearwater, Florida. Founded in 2006, the company provides end-to-end small molecule drug product development services spanning formulation design, analytical and stability testing, cGMP clinical manufacturing, and commercial manufacturing. CoreRx serves pharmaceutical and biotechnology companies requiring specialized capabilities in spray drying, particle engineering, oral bioavailability enhancement, multiparticulates, modified release formulations, oral solids and liquids, topical formulations, and powders for inhalation. The company emphasizes a domestic U.S. manufacturing footprint across three locations in Oregon, Georgia, and Florida, positioning itself as a supply-chain-resilient alternative to offshore CDMOs. Notable specialized offerings include complex oral dosage forms, advanced spray drying capabilities (with newly expanded commercial-scale suites in Bend, Oregon), and an integrated 'High Science / High Service' model that bundles preformulation through commercial manufacturing under one organizational roof.

The business operates on a project-based professional services model, generating revenue through negotiated contracts tied to formulation development, clinical manufacturing, and commercial supply scopes. Go-to-market is B2B enterprise field sales, with direct engagement of pharmaceutical sponsors and senior presence at industry conferences such as CPHI Milan. Pricing is not publicly disclosed and is described as quote-based on project scope. In April 2024, CoreRx acquired Societal CDMO, Inc. for approximately $130 million via tender offer, delisting Societal from Nasdaq and absorbing it as a wholly owned subsidiary; the combined entity was subsequently rebranded under the unified Bend Bioscience identity in September 2025. The company currently employs 101-250 people and has raised approximately $15 million across three funding rounds between 2015 and 2019. Leadership includes Todd R. Daviau as President and CEO, Bill Reid as Executive Director and Chief Operations Officer, and Bob Berg as Chief Financial Officer.

CoreRx firmographics

Firmographics
Name
CoreRx
Legal name
CoreRx, Inc.
Website
https://corerxpharma.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Short description
CoreRx (now Bend Bioscience) is a privately held U.S. pharmaceutical CDMO providing end-to-end small molecule drug product development and manufacturing services — formulation design, analytical, clinical, and commercial cGMP manufacturing — to pharmaceutical and biotechnology companies across three U.S. locations.
Ownership category
akta.pro rank

CoreRx industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Pharmaceutical CDMO
  • Contract manufacturing
  • Drug formulation development
  • Small molecule manufacturing
  • CGMP clinical manufacturing

Where CoreRx is headquartered

Location

Headquarters

HQ city
Clearwater
HQ country
United States
HQ region
North America

Offices3 records

Markets served

CoreRx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: CDMO services providing formulation development, analytical services, clinical manufacturing, and commercial manufacturing for pharmaceutical companies. Revenue generated through project-based contracts for drug development and manufacturing services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

CoreRx product offering

Product offering

Core offering

CoreRx is a pharmaceutical contract development and manufacturing organization (CDMO) providing integrated formulation development, analytical, clinical manufacturing, and commercial manufacturing services for small molecule therapeutics. Its offerings span Design, Develop, and Manufacture service tiers with specialized capabilities in spray drying, particle engineering, oral bioavailability enhancement, multiparticulates, modified release, oral solids, oral liquids, powders for inhalation, and topicals. Operations are supported through three U.S. manufacturing locations in Oregon, Georgia, and Florida, with newly expanded cGMP suites in Bend, Oregon.

Product overview

CoreRx operates as a pharmaceutical finished product Contract Development and Manufacturing Organization (CDMO), unified with Societal CDMO and Bend Bioscience under the Bend Bioscience brand. The company offers an integrated platform spanning Design, Develop, and Manufacture services for small molecule therapeutics. The portfolio includes specialized formulation capabilities such as Oral Bioavailability Enhancement (spray drying, particle engineering), Multiparticulates, Modified Release, Oral Dosage Form Design, Oral Solids, Oral Liquids, Powders for Inhalation, and Topicals. Service offerings encompass the full product lifecycle from Preformulation & Process Design through Analytical & Stability testing, cGMP Clinical Manufacturing, Commercial Manufacturing, Technology Transfer, Packaging, and Quality & Compliance. The company maintains world-class expertise across three U.S. locations in Oregon, Georgia, and Florida, with expanded cGMP capabilities in Bend, Oregon supporting spray drying, particle engineering, and complex oral dosage forms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Design Services

Companies that use CoreRx

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

CoreRx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

CoreRx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Starton TherapeuticsnotableStrategic or Co-development Partner · 4 April 2025Development agreement for oral controlled release dosage form of STAR-LLD (lenalidomide), representing a co-development partnership for specialized pharmaceutical formulation.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

CoreRx competitors and assessment

Company assessment

Direct peers

  • Recipharm: European-headquartered CDMO focused on oral solids, inhalation, and topical dosage forms, with both clinical and commercial manufacturing. Closely comparable in scope to CoreRx's specialty small molecule drug product platform.
  • Aenova Group: Pharmaceutical CDMO providing solid, semi-solid, and liquid dosage form development and manufacturing, including topicals and softgel capabilities—comparable dosage form breadth to CoreRx.
  • Hovione: Specialty CDMO focused on particle engineering, spray drying, and bioavailability enhancement for oral dosage forms—directly comparable to CoreRx's spray drying and particle engineering 'High Science' platform.
  • Catalent: Global CDMO offering formulation development, clinical and commercial manufacturing across oral, sterile, and inhalation dosage forms—directly comparable to CoreRx's small molecule drug product CDMO platform, though at much larger scale.
  • Lonza: One of the world's largest CDMOs providing small molecule and biologic drug substance and drug product services. Comparable as a full-service pharmaceutical CDMO, with overlapping oral solid dose and complex formulation capabilities.
  • Almac Group: Privately held pharmaceutical CDMO offering formulation development, analytical services, and clinical/commercial manufacturing for solid oral dosage forms, with similar integrated service scope to CoreRx.
  • Cambrex: CDMO providing small molecule API and finished dose development and manufacturing services, including controlled substances and high-potency compounds—comparable small molecule drug product focus.
  • Societal CDMO: Now a wholly owned subsidiary of CoreRx following the $130M 2024 acquisition; provides contract development and manufacturing for complex oral, topical, and nasal dosage forms, directly overlapping with CoreRx's formulation services.
  • Bend Bioscience: Bend Bioscience was combined with CoreRx and Societal CDMO under a unified brand in September 2025, and historically offered formulation and GMP spray drying services—directly comparable specialized CDMO capability, now the parent brand.

Broad incumbents

  • Thermo Fisher Scientific (Patheon): Operates a major pharmaceutical services division including oral solid dose, sterile, and API CDMO services. Overlaps directly with CoreRx's small molecule drug product offering as part of a much broader life sciences services portfolio.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

CoreRx social profiles

Digital presence

CoreRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CoreRx leadership team

Management profile

Number of profiles

Profiles3 records

CoreRx subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CoreRx funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CoreRx M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoreRx

What does CoreRx do?

CoreRx is a pharmaceutical contract development and manufacturing organization (CDMO) providing integrated formulation development, analytical, clinical manufacturing, and commercial manufacturing services for small molecule therapeutics. Its offerings span Design, Develop, and Manufacture service tiers with specialized capabilities in spray drying, particle engineering, oral bioavailability enhancement, multiparticulates, modified release, oral solids, oral liquids, powders for inhalation, and topicals. Operations are supported through three U.S. manufacturing locations in Oregon, Georgia, and Florida, with newly expanded cGMP suites in Bend, Oregon.

Is CoreRx a public or private company?

CoreRx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was CoreRx founded?

CoreRx was founded in 2006. It employs 101 to 250 people.

Where is CoreRx based?

CoreRx is headquartered in Clearwater, United States, in the North America region.

How does CoreRx make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are CoreRx's main competitors?

Direct peers on record are Recipharm, Aenova Group, Hovione, Catalent, Lonza, Almac Group, Cambrex, Societal CDMO and Bend Bioscience. Thermo Fisher Scientific (Patheon) is listed as a broad incumbent.

Does CoreRx have an API?

No public API is recorded for CoreRx.

What industry is CoreRx in?

CoreRx's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 3254 and its SIC code is 2890.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireFormulation Development Outsourcing Market Report 2026The formulation development outsourcing market is forecast to grow from $32.32 billion in 2025 to $35.45 billion in 2026 at a 9.7% CAGR, reaching $53.3 billion by 2030 with a 10.7% CAGR, driven by demand for biologics, personalized medicine, and advanced formulation technologies. The industry is increasingly adopting AI-powered platforms like NVIDIA's BioNeMo Cloud and outsourcing complex drug formulations, with North America leading the global market in 2025. In April 2024, CoreRx, Inc. acquired Societal CDMO Inc. to expand its formulation development and scale-up manufacturing capabilities.GlobeNewswireTopical Drugs Contract Development and Manufacturing Organization (CDMO) Market Research Report 2026: $121 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts 2020-2035The global topical drugs CDMO market is projected to grow from $61.16 billion in 2025 to $70.96 billion in 2026, a 16% CAGR, and further to $121.22 billion by 2030. Growth is driven by pharmaceutical outsourcing, rising dermatological conditions, and cost optimization, with Asia-Pacific dominating in 2025.YahooTopical Drugs Contract Development and Manufacturing Organization (CDMO) Market Research Report 2026: $121 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts 2020-2035The global topical drugs CDMO market is projected to grow from $61.16 billion in 2025 to $70.96 billion in 2026, reaching $121.22 billion by 2030, driven by pharmaceutical outsourcing, rising dermatological conditions, and regulatory complexities. Key market activity includes CoreRx Inc.'s acquisition of Societal CDMO Inc. for $130 million in April 2024 and SOHM Inc.'s launch of a GMP-compliant topical production facility in Carlsbad in November 2023. Asia-Pacific dominated the market in 2025, though tariffs have influenced regional manufacturing costs and supply chain strategies.YahooTopical Drugs Contract Development and Manufacturing Organization (CDMO) Market Research Report 2026: $121 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts 2020-2035ResearchAndMarkets.com published a market report projecting the global topical drugs contract development and manufacturing organization (CDMO) market to grow from $61.16 billion in 2025 to $121.22 billion by 2030, representing a compound annual growth rate of 14.3%. The market expansion is driven by rising pharmaceutical outsourcing, increasing prevalence of dermatological conditions, and growing demand for complex topical formulations and transdermal drug platforms. Notable recent developments include CoreRx Inc.'s acquisition of Societal CDMO Inc. for $130 million in April 2024 and SOHM Inc.'s launch of a GMP-compliant topical production facility in Carlsbad in November 2023.GlobeNewswireSmall Molecule Innovator CDMO Research Report 2026: $93.12 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe small molecule innovator CDMO market is projected to grow from $60.7 billion in 2025 to $93.12 billion by 2030, driven by rising R&D costs, patent expirations, and increased outsourcing by biotech firms. Asia-Pacific emerged as the largest regional market by 2025, though tariff pressures are prompting investments in regional sourcing and domestic manufacturing. Strategic partnerships and acquisitions are reshaping the competitive landscape, including SST Corporation's partnership with Viwit Pharmaceuticals and CoreRx's acquisition of Societal CDMO.YahooSmall Molecule Innovator CDMO Research Report 2026: $93.12 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe small molecule innovator CDMO market is projected to grow from $60.7 billion in 2025 to $93.12 billion by 2030, driven by rising R&D costs, patent expirations, and increased outsourcing by biotech firms. Strategic partnerships and acquisitions are actively shaping market evolution, including SST Corporation's partnership with Viwit Pharmaceuticals in August 2023 and CoreRx, Inc.'s acquisition of Societal CDMO, Inc. in April 2024. Tariffs on imported materials are increasing production costs for firms in Asia-Pacific and Europe, prompting investments in regional sourcing and domestic manufacturing to enhance supply chain resilience.YahooSmall Molecule Innovator CDMO Research Report 2026: $93.12 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FResearchAndMarkets.com has published the Small Molecule Innovator CDMO Market Report 2026, projecting the market to grow from $60.7 billion in 2025 to $93.12 billion by 2030 at a CAGR of 8.4%. Key growth drivers include rising R&D costs, patent expirations, increasing outsourcing by biotech firms, and the prevalence of chronic diseases affecting 76.4% of U.S. adults according to the CDC. Strategic transactions such as CoreRx's April 2024 acquisition of Societal CDMO and SST Corporation's August 2023 partnership with Viwit Pharmaceuticals are highlighted as examples of market consolidation and collaboration.EIN PresswireTampa Telecomm Meets the Eye of the Storm: How a Local Rep is Powering Hurricane PreparednessDarius McGrew, a Frontier Communications account executive, uses AI-driven analytics to segment enterprise customers by risk zone, infrastructure resilience, and historical outage patterns. He tailored storm-readiness packages for clients like CoreRX, which faced connectivity issues during Hurricane Helene. His work aims to make AI a proactive tool for hurricane preparedness.BendbioscienceCoreRx, Societal CDMO, and Bend Bioscience Unite Under the Bend Bioscience Brand to Provide World Class CDMO OfferingCoreRx, Societal CDMO, and Bend Bioscience have announced their unification under the Bend Bioscience brand to form a comprehensive contract development and manufacturing organization (CDMO). The merged entity combines CoreRx’s formulation development expertise, Societal CDMO’s manufacturing capabilities, and Bend Bioscience’s research leadership to offer end-to-end drug development services. This strategic move aims to enhance operational efficiencies and accelerate the delivery of therapies to global markets.PharmoutsourcingContract Manufacturing from CoreRx, IncCoreRx, Inc. is a contract pharmaceutical manufacturing company that provides cGMP-compliant development and production services for various clinical dosage forms. The firm specializes in small-scale manufacturing needs, offering capabilities such as process scale-up, placebo matching for clinical studies, and packaging of complex delivery systems.